Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | March 06, 2023 | March 09, 2023 |
| Cardiovascular Systems IncCSII · Entity 114141 | Director | November 18, 2016 | November 21, 2016 |
| Outset Medical, Inc.OM · Entity 7026 | Director · Chair and CEO | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date March 06, 2023 · Filed March 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,907 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Grant · Acquired 14,775 · Balance 25,907 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 23,329 |
Reported balance
After 2023-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-06 · Grant · Acquired 23,329 · Balance 23,329 F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.
Cardiovascular Systems Inc
Report date November 18, 2016 · Filed November 21, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,791 |
Reported balance
After 2016-11-18 transaction · row 1
1 source rowRow 1 · 2016-11-18 · Sale · Disposed 7,500 · Balance 14,791 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.75 to $27.03 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trigg Family Trust | 2,491 |
Reported balance
Holding disclosure · report date 2016-11-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,491 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 38,950 |
Reported balance
Holding disclosure · report date 2016-11-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 38,950 F2: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment, and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership. F3: Represents the aggregate number of restricted stock units (all previously reported) held by reporting person that are payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,949 |
Reported balance
Holding disclosure · report date 2016-11-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 5,949 F4: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,488 shares on September 30, 2016 and 1,487 shares on each of December 31, 2016, March 31, 2017 and June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.75 to $27.03 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment, and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership.
F3: Represents the aggregate number of restricted stock units (all previously reported) held by reporting person that are payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership.
F4: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,488 shares on September 30, 2016 and 1,487 shares on each of December 31, 2016, March 31, 2017 and June 30, 2017.
Outset Medical, Inc.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,597 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 3,437 · Balance 194,597 F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 9,319 shares of Common Stock underlying RSUs granted to the reporting person on January 12, 2024 and June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectTrigg 2002 Rev Trust | 41,666 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 41,666 |
| Common StockSEC Table I · non-derivative | IndirectTrigg Family Trust | 584 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 584 |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 9,319 shares of Common Stock underlying RSUs granted to the reporting person on January 12, 2024 and June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed August 01, 2024
Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Disposition to issuer · Disposed 3,244 · Balance 13,925 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 13,925 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2021 Filed Sep 1, 2021 23:49 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001484612-21-000055 · edgardoc.xml · derivative · entry 6 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,873 Underlying: Common Stock · 15,000 shares Expires 2025-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on August 22, 2015. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:49 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 5,000 | $49.17 | $245,838.00 |
DisclosureSEC source: 0001484612-21-000055 · edgardoc.xml · nonDerivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.63 to $49.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:49 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 5,000 | $2.93 | $14,650.00 |
DisclosureSEC source: 0001484612-21-000055 · edgardoc.xml · nonDerivative · entry 3 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:49 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 15,000 | $49.16 | $737,356.50 |
DisclosureSEC source: 0001484612-21-000055 · edgardoc.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.55 to $49.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:49 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 15,000 | $2.93 | $43,950.00 |
DisclosureSEC source: 0001484612-21-000055 · edgardoc.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:59 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001484612-21-000046 · edgardoc.xml · derivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,873 Underlying: Common Stock · 20,000 shares Expires 2025-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on August 22, 2015. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:59 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 20,000 | $40.62 | $812,306.00 |
DisclosureSEC source: 0001484612-21-000046 · edgardoc.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $40.01 to $41.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Due to an administrative error, shares acquired by the reporting person under the Issuer?s Employee Stock Purchase Plan on February 28, 2021 were incorrectly reported as 1,666 shares instead of 1,265 shares in a Form 4 filed on March 17, 2021. This column reflects the corrected balance. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:59 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 20,000 | $2.93 | $58,600.00 |
DisclosureSEC source: 0001484612-21-000046 · edgardoc.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,919 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · derivative · entry 13 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,873 Underlying: Common Stock · 6,919 shares Expires 2025-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on August 22, 2015. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · derivative · entry 12 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,792 Underlying: Common Stock · 10,000 shares Expires 2025-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on August 22, 2015. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · derivative · entry 11 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,792 Underlying: Common Stock · 12,500 shares Expires 2025-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on August 22, 2015. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,081 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · derivative · entry 10 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,081 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on December 17, 2014. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 13,081 | $49.25 | $644,247.10 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 8 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.65 to $50.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 13,081 | $1.11 | $14,519.91 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 7 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 6,919 | $49.25 | $340,764.90 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 6 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.65 to $50.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 6,919 | $2.93 | $20,272.67 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 5 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 10,000 | $49.23 | $492,337.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.65 to $50.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 10,000 | $2.93 | $29,300.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 3 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 12,500 | $49.25 | $615,621.25 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.65 to $50.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 12,500 | $2.93 | $36,625.00 |
DisclosureSEC source: 0001484612-21-000037 · edgardoc.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:26 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000011 · edgardoc.xml · derivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,081 Underlying: Common Stock · 20,000 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on December 17, 2014. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:26 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 20,000 | $47.90 | $957,930.00 |
DisclosureSEC source: 0001484612-21-000011 · edgardoc.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $47.45 to $48.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: These shares of common stock of the Issuer ("Shares") are held directly by the Trigg Family Trust U/A DTD 1/1/2002, for which the reporting person and her spouse serve as trustees. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:26 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 20,000 | $1.11 | $22,200.00 |
DisclosureSEC source: 0001484612-21-000011 · edgardoc.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:19 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0000905148-21-000432 · form4.xml · derivative · entry 6 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,081 Underlying: Common Stock · 20,000 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on December 17, 2014. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:19 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 646 | $59.82 | $38,645.01 |
DisclosureSEC source: 0000905148-21-000432 · form4.xml · nonDerivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $59.77 to $60.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:19 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 3,592 | $58.73 | $210,953.13 |
DisclosureSEC source: 0000905148-21-000432 · form4.xml · nonDerivative · entry 3 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,304 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $58.404 to $59.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:19 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 15,762 | $57.83 | $911,470.75 |
DisclosureSEC source: 0000905148-21-000432 · form4.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,896 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $57.34 to $58.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:19 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 20,000 | $1.11 | $22,200.00 |
DisclosureSEC source: 0000905148-21-000432 · form4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,697 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · derivative · entry 9 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,081 Underlying: Common Stock · 14,697 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on December 17, 2014. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,037 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · derivative · entry 8 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,037 shares Expires 2024-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on October 5, 2014. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,766 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · derivative · entry 7 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,766 shares Expires 2023-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on May 1, 2012. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 29,962 | $55.74 | $1,670,180.75 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · nonDerivative · entry 5 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F7 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $55.28 to $56.235, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6). Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 27,538 | $55.00 | $1,514,716.67 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · nonDerivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,620 F7 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $54.23 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5). Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 14,697 | $1.11 | $16,313.67 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · nonDerivative · entry 3 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 19,037 | $1.11 | $21,131.07 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 23,766 | $1.11 | $26,380.26 |
DisclosureSEC source: 0001140361-21-011509 · form4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 11,109 | $0.00 Strike: $45.01 | $0.00 |
DisclosureSEC source: 0001209191-21-022203 · doc4.xml · derivative · entry 2 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109 Underlying: Common Stock · 11,109 shares Expires 2031-03-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 17, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 4,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022203 · doc4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:12 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantStock Option (Right to Buy) · Derivative | 57,937 | $0.00 Strike: $25.89 | $0.00 |
DisclosureSEC source: 0001140361-21-008973 · form4.xml · derivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,937 Underlying: Common Stock · 57,937 shares Expires 2031-03-14 F5 · derivative.exercise_date: This option vests 25% on March 15, 2022, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:12 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 58,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-008973 · form4.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,658 F4 · shares: Represents performance stock units ("PSU") granted to the reporting person on March 15, 2021. Each PSU represents a contingent right to receive one share of common stock. These PSUs shall vest (i) 50% on the last day of any period of 30 consecutive trading days during which the closing price is greater than $75.00 per share on each trading day during such period, subject to the reporting person's continued employment through the applicable vesting date and (ii) 50% shall vest on the last day of any period of 30 consecutive trading days during which the closing price is greater than $90.00 per share on each trading day during such period, subject to the reporting person's continued employment through the applicable vesting date. F3 · balance_after: Includes 1,666 shares acquired under the Outset Medical Inc. Employee Stock Purchase Plan on February 28, 2021. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:12 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 29,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-008973 · form4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,383 F2 · shares: Represents restricted stock units ("RSU") granted to the reporting person on March 15, 2021. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest 25% on March 15, 2022, then quarterly over three years on each February 15th, May 15th, August 15th and November 15th, subject to the reporting person's continuous service through the applicable vesting date. F3 · balance_after: Includes 1,666 shares acquired under the Outset Medical Inc. Employee Stock Purchase Plan on February 28, 2021. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 19:12 UTC Amendment | Outset Medical, Inc. OM · Entity 7026 | GrantStock Option (Right to Buy) · Derivative | 57,937 | $0.00 Strike: $50.01 | $0.00 |
DisclosureSEC source: 0001140361-21-009051 · form4.xml · derivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,937 Underlying: Common Stock · 57,937 shares Expires 2031-03-14 F2 · derivative.exercise_price: This Form 4 amendment is being filed to correct the exercise price. F1 · derivative.exercise_date: This option vests 25% on March 15, 2022, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 00:22 UTC | Outset Medical, Inc. OM · Entity 7026 | ConversionSeries D Redeemable Convertible Preferred Stock · Derivative | 16,078 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-020793 · form4.xml · derivative · entry 5 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trigg Family Trust U/A DTD 01/01/2002 Disclosed balance after: 0 Underlying: Common Stock · 2,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F5 · price: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F5 · derivative.exercise_date: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F5 · derivative.expiration_date: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F1 · ownership.direct: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. F1 · ownership.nature: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 00:22 UTC | Outset Medical, Inc. OM · Entity 7026 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 38,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-020793 · form4.xml · derivative · entry 4 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trigg Family Trust U/A DTD 01/01/2002 Disclosed balance after: 0 Underlying: Common Stock · 4,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F4 · price: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F4 · derivative.exercise_date: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F4 · derivative.expiration_date: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F1 · ownership.direct: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. F1 · ownership.nature: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 00:22 UTC | Outset Medical, Inc. OM · Entity 7026 | ConversionCommon Stock | 7,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-020793 · form4.xml · nonDerivative · entry 2 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trigg Family Trust U/A DTD 01/01/2002 Disclosed balance after: 8,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This option vested in 48 equal monthly installments beginning on December 17, 2014. F3 · price: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. F1 · ownership.direct: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. F1 · ownership.nature: These shares of common stock of the Issuer ("Shares") are held directly by The Trigg Family Trust U/A DTD 01/01/2002, for which the reporting person and her spouse serve as trustees. Read SEC document |
| August 17, 2020 Filed Sep 18, 2020 00:22 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,355 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001140361-20-020793 · form4.xml · derivative · entry 3 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,778 Underlying: Common Stock · 68,355 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. F3 · shares: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. F2 · derivative.exercise_date: This option vested in 48 equal monthly installments beginning on December 17, 2014. F3 · derivative.underlying_shares: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. F3 · balance_after: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. Read SEC document |
| August 17, 2020 Filed Sep 18, 2020 00:22 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 68,355 | $1.11 | $75,874.05 |
DisclosureSEC source: 0001140361-20-020793 · form4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. F3 · price: This option has been adjusted to reflect the 1-for-7.9 reverse stock split that occurred on September 8, 2020. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 16:40 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | SaleCommon Stock | 7,500 | $26.84 | $201,313.50 |
DisclosureSEC source: 0000914190-16-000883 · edgar.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,791 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.75 to $27.03 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.